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the injection. The samples were frozen and stored at -20 ° C 
until assayed. 
The assay of cefotaxime and desacetyt cefotaxime by HPLC or 
bioassay with Escherichia coti V 6311/65 were described in detail 
in our previous paper (1). 
Results 
Figure 1 shows the average time-concentration curves of 
cefotaxime and desacetyl cefotaxime in the bile of eight 
patients following an i.v. injection of 2 g. Because the test 
organism is slightly susceptible to desacetyl cefotaxime, 
the concentrations of the parent compound are over- 
estimated by the microbiological method. 1.5 h after the 
Introduction 
In a previous paper we reported on the determination of
cefotaxime and desacetyl cefotaxime in human and rat 
serum after an i.v. injection of this cephalosporin (1); the 
concentrations of the parent compound and its metabolite 
in human bile were also briefly described. 
It has been shown that older cephalosporins with a 3~ 
acetoxymethyl substituent, e. g. cephalothin, are meta- 
bolised to the respective desacetyl compounds (2). The 
degradation of cefotaxime to desacetyl cefotaxime has 
also been observed in man and was simultaneously 
reported from other laboratories (3, 4). 
The purpose of this paper is to report in detail on the 
concentrations of cefotaxime and its antimicrobially 
active metabolite in human bile, measured both by high 
performance liquid chromatography (HPLC) and by 
bioassay with a selective test organism after an i.v. injec- 
tion of 2 g. 
Patients and Methods 
Ten patients, three men and seven women aged between 32 and 
82 years, were given a loading dose of 2 g cefotaxime adminis- 
tered i.v. over 3 min. The patients were selected for the study if 
physical examination suggested an infection of the gall bladder. 
None of the patients had received any antibacterial drugs 
beforehand. Informed written consent was obtained from each 
patient. 
Bile was collected through a catheter inserted into he bile duct 
as for ERCP and collected in nine fractions: before the injection 
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Figure 1 : Concentrations of cefotaxime (O, A) and desacetyl 
cefotaxime (O) in human bileafter an i.v. injection of 2 g. 
O-~Q,  0 0 = high perfOrmance liquid chromatogra- 
phy; A A = bioassay. 
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injection, the desacetyl cefotaxime concentration 
exceeded the concentration of the parent drug and 
remained higher during the period of investigation. 
Because the values found in Patients 3 and 10 differed so 
widely from those of the other patients, individual values 
of the concentrations of the parent compound and its 
metabolite assayed in the bile of all patients are given in 
Table 1. 
Discussion 
After an i.v. injection of 2 g cefotaxime, the parent 
compound and its microbiologically active desacetyl 
metabolite were demonstrated in the bile of all patients 
investigated. The concentrations of both cefotaxime and 
desacetyl cefotaxime were 2-3 fold higher in the bile of 
younger patients (Patient 3, 44 years and Patient 10, 32 
years) than in the eight patients aged 58-82 (Table 1). 
Moreover, the formation of desacetyl cefotaxime seemed 
to be impaired in Patient 2 (Table 1), possibly due to 
insufficiency of liver function (5). 
The biliary concentrations of cefotaxime are about ten 
times lower than cefoperazone concentrations following 
i.v. administration (6). Nevertheless, the concentrations 
of cefotaxime assayed in the bile are higher than most of 
the minimal inhibitory concentrations tested with a vari- 
ety of strains, e.g. Proteus mirabilis ATCC 14273, 
Table 1: Individual concentrations of 
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Pseudomonas aeruginosa K 1118 and E. coli V 6311/65 
(1, 7-9). On the other hand, high antibiotic oncentra- 
tions in serum seem to be more important than bile levels 
of antibiotics in reducing the risk of infectious complica- 
tions following gall bladder extirpation (10, 11). 
Cephalosporins usually achieve gh concentrations in the 
bile (12-16) and are generally highly effective against 
those organisms most commonly isolated from the biliary 
tract (17). 
Therefore, preoperative administration f cephalosporins 
such as cefotaxime should reduce the risk of infectious 
complications during complicated cholecystectomy when 
anti-infective prophylaxis i  indicated (18). 
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